Aspeya

What Aspeya does

Aspeya is a wellness and healthcare company organized as Philip Morris International's dedicated wellness unit, operating as a separately governed Connecticut-incorporated entity headquartered in Stamford, USA, with operational hubs in Denmark, Switzerland, the UK, Canada, Singapore, Malaysia, and India, and a workforce of more than 1,400 specialists. The company was formed in March 2022 through PMI's acquisition of Fertin Pharma, Vectura Group PLC, and OtiTopic, originally operating as Vectura Fertin Pharma before rebranding to Aspeya on March 4, 2025, following the December 2024 divestment of Vectura Group to Molex for GBP 150M upfront plus up to GBP 148M in deferred consideration. Its portfolio is built around four focus areas: consumer wellness (purposeful energy products targeting physical and mental energy needs), medical and non-recreational cannabinoids (through its independently governed Verdeya subsidiary), inhaled therapeutics (the investigational ASY202 multidose dry-powder inhaler delivering dihydroergotamine for acute migraine, with Phase 1 data showing median Tmax under 10 minutes and Phase 2 trials initiated May 2026), and nicotine replacement therapy.

Underlying technology is centered on oral and intra-oral delivery systems and inhaled drug-device combinations developed and manufactured by its wholly-owned Danish CDMO Fertin Pharma A/S, which provides proprietary platforms for lozenges, tablets, and a novel multidose DPI used in ASY202. The business model combines contract development and manufacturing services (Fertin Pharma CDMO), consumer wellness product sales (proprietary and co-developed), prescription drug-device commercialization (ASY202, contingent on regulatory approval), and commercial-scale cannabinoid products (Verdeya plus the Luo CBD lozenge manufactured via subsidiary Cogent and distributed through Aurora Cannabis's Canadian direct-to-patient platform since September 2024). Customer segments span enterprise pharma/wellness partners, medical cannabis patients via Aurora's platform, and health-conscious consumers, with go-to-market executed through a co-development/co-commercialization partnership model leveraging partners' existing sales and marketing capabilities alongside internal commercial infrastructure.

Name

Aspeya

Legal name

Aspeya, Inc.

Website

https://aspeya.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Aspeya is PMI's wholly-owned wellness and healthcare company developing consumer wellness products, medical cannabinoid products (via Verdeya), and the clinical-stage inhaled migraine therapy ASY202, leveraging its Fertin Pharma oral and intra-oral delivery CDMO and a partnership-based go-to-market model.

Ownership category

akta.pro rank

Product category

Pharmaceutical and Consumer Wellness Products

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254), Food (Health) Supplement Retailers (456191)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro industry

PRIMARYHLAIADAG

Sleep, Stress & Mood Support

Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

SECONDARYCRADAGAD

Herbal & Botanical Supplements

Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Vitamins, Supplements & Sports Nutrition

SECONDARYCRANAHAC

CBD/Hemp Wellness & Supplements Retail

Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Specialty Retail (CBD/Hemp & Accessories)

SECONDARYAFAFAFAF

Botanical/Herbal & Adaptogen Functional Beverage Production

Agriculture & Food Production/Beverage Production/Functional & Nutritional Beverage Production (Energy, Sports, Fortified)

Keywords

• Pharmaceutical development
• Cannabinoid therapeutics
• Nicotine replacement therapy
• Oral drug delivery
• Contract manufacturing

Headquarters

HQ city

Stamford

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Consumer Wellness Products: Sale of consumer wellness products targeting the energy segment with healthier, holistic solutions to support physical and mental energy levels. Revenue generated through proprietary products and co-commercialized offerings with partners.
2. Cannabinoid Products (Verdeya): Development and commercialization of medical and non-recreational cannabinoid products through Verdeya subsidiary. Products include CBD lozenges and future medical cannabis portfolio.
3. CDMO Services: Contract development and manufacturing organization services through Fertin Pharma, providing oral and intra-oral delivery systems manufacturing capabilities to external clients.
4. Inhaled Therapeutics: Development of prescription drug-device combination products like ASY202 for acute migraine treatment. Revenue potential upon regulatory approval and commercialization.
5. Investment Returns: Aspeya took a minority stake in waterdrop as part of the €100M+ funding round, generating investment returns through equity appreciation.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Aspeya develops and commercializes pharmaceutical and consumer wellness products across three focus areas: consumer wellness (purposeful energy products targeting healthier physical and mental energy), cannabinoids (via Verdeya subsidiary for medical and non-recreational use), and inhaled therapeutics (ASY202, an investigational DHE dry-powder inhaler for acute migraine). The company leverages Fertin Pharma's proprietary oral and intra-oral drug delivery technology platform and CDMO capabilities, and also develops nicotine replacement therapy products to support adult smokers transitioning to healthier lifestyles.

Product overview

Aspeya operates as a wellness and healthcare company with a multi-product portfolio organized around four focus areas: Consumer wellness (energy products), cannabinoids (via Verdeya subsidiary), inhaled therapeutics (ASY202 for migraine), and nicotine replacement therapy. The company develops and commercializes differentiated products and brands addressing unmet patient and consumer needs. Aspeya benefits from access to Fertin Pharma's oral technology platform (a wholly owned CDMO subsidiary) for oral and intra-oral delivery systems. The company operates under Philip Morris International ownership and leverages scientific expertise, innovation, and rigorous scientific standards to reimagine how ingredients can be used.

Differentiator

Problem solved

Functional benefit

Brands

• Verdeya: Cannabinoid products brand focusing on medical and non-recreational cannabinoid products with a patient and consumer-first mindset

Products and services

• Consumer Wellness Products Consumer wellness products in the Purposeful Energy segment offering healthier, holistic solutions to support physical and mental energy levels, developed and co-commercialized in partnership with companies having existing sales and marketing capabilities.
• Cannabinoid Products (Verdeya) Best-in-class medical and non-recreational cannabinoid products developed through Verdeya subsidiary, combining scientific approach, technical expertise, and real-world patient data with commitment to consistent, high standards for quality, safety, and reliability.
• ASY202 Investigational oral inhalation drug-device combination product containing dihydroergotamine mesylate (DHE) as dry powder formulation delivered via novel multidose dry powder inhaler (DPI), in development for acute treatment of migraine with or without aura in adults.
• Luo CBD Lozenge Medical cannabis CBD lozenge with novel dissolvable format that is easy to dose, launched as the first medical cannabis CBD lozenge in Canada through collaboration with Aurora Cannabis.
• Nicotine Replacement Therapy Products Nicotine replacement therapy products developed to support adult smokers in quitting and transitioning to healthier lifestyles, leveraging Fertin Pharma's oral and intra-oral delivery technology.
• CDMO Services (Fertin Pharma) Contract development and manufacturing organization services providing development and manufacturing of innovative oral and intra-oral delivery systems (lozenges, tablets, and other oral formats) to external pharmaceutical and wellness clients.

Quantifiable outcome

• Phase 1 trials showed inhaled ASY202 achieved rapid systemic absorption with median Tmax < 10 minutes
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• VerdeyacoreStrategic or Co-development Partner · 14 August 2025Verdeya is a wholly owned subsidiary of Aspeya that functions as an independent legal and operational entity. It develops and commercializes best-in-class medical and non-recreational cannabinoid products, combining scientific strength, technical expertise, and data-driven insights. Verdeya maintains full accountability for strategic direction, operational execution, and financial stewardship.
• Aurora CannabiscoreStrategic or Co-development Partner · 1 August 2024Commercial collaboration between Cogent International (Vectura Fertin Pharma subsidiary) and Aurora Cannabis. Cogent manufactures and launches CBD lozenge products on Aurora's Canadian medical cannabis patient platform. Following successful launch, collaboration may expand to other medical cannabis products in Canada. Initial term of 24 months.
• Fertin PharmacoreTechnology or Integration · 1 March 2022Fertin Pharma is a wholly owned subsidiary of Aspeya and a contract development and manufacturing organization (CDMO). It provides access to oral technology platform and develops and manufactures innovative oral and intra-oral delivery systems. Aspeya benefits from Fertin's innovation, product development, and supply capabilities.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Canopy Growth: Canadian medical and recreational cannabis producer with global footprint including CBD wellness products. Canopy Growth is a direct competitor in the medical and consumer cannabinoid category where Verdeya operates.
• Jazz Pharmaceuticals: Acquired MAP Pharmaceuticals and its inhaled DHE product (now marketed as Trudhesa) for acute migraine. Jazz is the most direct competitor to Aspeya's ASY202 program in the inhaled DHE / acute migraine space, sharing the same active ingredient and a similar patient target.
• Aurora Cannabis: Aspeya's distribution partner for Luo CBD lozenge in Canada and a leading Canadian medical cannabis producer. Aurora is both a customer/partner and the most direct operational peer for Verdeya's medical cannabinoid strategy, competing for the same Canadian patient base.
• Tilray Brands: Global cannabis and wellness company with a significant medical cannabis franchise in Canada, Europe and Australia. Tilray is a direct competitor to Verdeya's medical cannabinoid platform, with overlapping geographic focus and broader consumer brand reach.
• Catalent: Global CDMO with deep capabilities in oral dose forms, softgel, and inhaled drug-device combinations. Catalent is the closest peer to Fertin Pharma's CDMO business and also a manufacturing services peer for ASY202-style inhaled programs.

Broad incumbents

• AbbVie: Through its Allergan acquisition, AbbVie markets Ubrelvy (oral CGRP) and previously commercialized the inhaled DHE franchise now at Jazz. AbbVie is the dominant incumbent in acute migraine with both CGRP and onabotulinumtoxinA franchises.
• Haleon: Spun out of GSK in 2022, Haleon owns global NRT and consumer health brands including Nicorette/Nicotinell, Centrum, and Panadol. Haleon is the broad incumbent that Aspeya must compete with across NRT and consumer wellness categories.
• Lonza Group: Global CDMO leader serving pharma and consumer health customers with oral, inhaled, and biologic capabilities. Lonza is a broad incumbent comparator for Fertin Pharma's CDMO positioning and scale.

Emerging players

• Organon & Co. Spun out of Merck in 2021 with a women's health and biosimilar focus. Organon is an emerging peer relevant to Aspeya's prescription drug development strategy and PMI-style conglomerate spin dynamics.
• AG1 / Athletic Greens: Direct-to-consumer wellness brand in the daily greens/supplement category that competes with Aspeya's consumer wellness "purposeful energy" positioning for similar premium, science-forward consumers.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aspeya

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aspeya